Longeveron Inc. (LGVN) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Longeveron Inc. is a clinical-stage biotechnology company developing laromestrocel, an allogeneic cellular therapy, for indications including Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD), and pediatric Dilated Cardiomyopathy (DCM). The company operates as a single segment focused on regenerative medicine.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenues | $137 | $773 | $834 | $1,789 |
| Net Loss | $(7,221) | $(4,419) | $(17,260) | $(11,892) |
| Operating Expenses | $7,435 | $5,331 | $18,434 | $13,595 |
| Cash and Equivalents (End of Period) | $9,244 (as of Sept 30, 2025) | |||
| Accumulated Deficit | $(126,867) (as of Sept 30, 2025) | |||
| Working Capital | $5,400 (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 82% in Q3 2025 compared to Q3 2024 ($137k vs $773k). This was driven by a 92% drop in contract manufacturing revenue due to the winding down of the "Secretome" agreement and a 55% decrease in clinical trial revenue from the Bahamas Registry.
- Increased Expenses: Operating expenses rose 39% in Q3 2025 ($7.4M vs $5.3M). Research and Development (R&D) expenses increased 75% ($3.9M vs $2.2M), primarily due to technology transfer costs and supplies for BLA-enabling activities. General and Administrative (G&A) expenses increased 15% ($3.6M vs $3.1M) due to personnel costs and severance.
- Widened Loss: Net loss increased 63% in Q3 2025 ($7.2M vs $4.4M) and 45% for the nine-month period ($17.3M vs $11.9M).
- Cash Burn: Net cash used in operating activities for the nine months ended Sept 30, 2025, was $13.3 million, compared to $10.5 million in the prior year period.
Guidance, Outlook, and Risks
- Liquidity and Going Concern: The company has raised substantial doubt about its ability to continue as a going concern. With $9.2 million in cash, management anticipates funding operations only until late Q1 2026. Additional financing is required to meet minimum expenditure commitments for the next 12 months.
- Capital Raising: In August 2025, the company closed a public offering raising approximately $5.0 million. In September 2025, it established an At-The-Market (ATM) facility for up to $10.7 million in share sales.
- Clinical Pipeline:
- HLHS: The ELPIS II Phase 2b trial is fully enrolled; top-line results are expected in Q3 2026. A potential BLA filing is targeted for 2027.
- Alzheimer's: Following a positive FDA Type B meeting, the company is seeking partnerships for a pivotal Phase 2/3 trial.
- DCM: FDA IND approved in July 2025; a Phase 2 pivotal trial is planned for 2026.
- Nasdaq Compliance Risk: On September 22, 2025, the company received notice of non-compliance with the $1.00 minimum bid price requirement. It has 180 days (until March 23, 2026) to regain compliance or face delisting.
- Government Shutdown: Ongoing U.S. federal government shutdown may delay regulatory communications with the FDA and SEC, potentially impacting clinical trial timelines and financing.
Investor Verification Checklist
- Verify the timeline and sufficiency of the upcoming capital raise to bridge the gap beyond Q1 2026.
- Monitor the stock price to assess the risk of Nasdaq delisting and potential reverse stock split actions.
- Confirm the status of the ELPIS II trial enrollment and any potential delays due to the government shutdown.
- Review the terms of the new ATM facility and the August 2025 offering for dilution impact.
- Assess the progress of partnership discussions for the Alzheimer's disease program to offset R&D costs.